Abstract:Numerous peptides inhibit the entry of enveloped viruses into cells. Some of these peptides have been shown to inhibit multiple unrelated viruses. We have suggested that such broad-spectrum antiviral peptides share a property called interfacial activity; they are somewhat hydrophobic and amphipathic, with a propensity to interact with the interfacial zones of lipid bilayer membranes. In this study, we further tested the hypothesis that such interfacial activity is a correlate of broad-spectrum antiviral activity. In this study, several families of peptides, selected for the ability to partition into and disrupt membrane integrity but with no known antiviral activity, were tested for the ability to inhibit multiple diverse enveloped viruses. These include Lassa pseudovirus, influenza virus, dengue virus type 2, herpes simplex virus 1, and nonenveloped human adenovirus 5. Various families of interfacially active peptides caused potent inhibition of all enveloped viruses tested at low and submicromolar concentrations, well below the range in which they are toxic to mammalian cells. These membrane-active peptides block uptake and fusion with the host cell by rapidly and directly interacting with virions, destabilizing the viral envelope, and driving virus aggregation and/or intervirion envelope fusion. We speculate that the molecular characteristics shared by these peptides can be exploited to enable the design, optimization, or molecular evolution of novel broad-spectrum antiviral therapeutics.IMPORTANCE New classes of antiviral drugs are needed to treat the ever-changing viral disease landscape. Current antiviral drugs treat only a small number of viral diseases, leaving many patients with established or emerging infections to be treated solely with supportive care. Recent antiviral peptide research has produced numerous membrane-interacting peptides that inhibit diverse enveloped viruses in vitro and in vivo Peptide therapeutics are becoming more common, with over 60 FDA-approved peptides for clinical use. Included in this class of therapeutics is enfuvirtide, a 36-residue peptide drug that inhibits HIV entry/fusion. Due to their broad-spectrum mechanism of action and enormous potential sequence diversity, peptides that inhibit virus entry could potentially fulfill the need for new antiviral therapeutics; however, a better understanding of their mechanism is needed for the optimization or evolution of sequence design to combat the wide landscape of viral disease.

In Vitro Antiviral Activity of Two Host Defense Peptides Against Human alphaherpesvirus 1

Antiviral Activities of Mastoparan-L-Derived Peptides against Human Alphaherpesvirus 1

Antiviral peptides as promising therapeutic drugs

In Vitro Profiling of the Antiviral Peptide TAT-I24

The antiherpetic and anti-inflammatory activity of the frog-derived peptide Hylin-a1

Inhibition of herpes simplex virus type 1 infection by cationic beta-peptides

Broad-Spectrum Antiviral Entry Inhibition by Interfacially Active Peptides

Antiviral activity of temporin-1CEb analogues against gingival infection with herpes simplex virus type 1

Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells

Exploring the Efficacy of Peptides and Mimics against Influenza A Virus, Adenovirus, and Murine Norovirus

Antiviral activity of the host defense peptide piscidin 1: investigating a membrane-mediated mode of action

Antiviral effect of peptoids on hepatitis B virus infection in cell culture

Host targeted antiviral (HTA): functional inhibitor compounds of scaffold protein RACK1 inhibit herpes simplex virus proliferation

Inhibition Activity of Herpes Virus (HSV) Replication by Α-Tif Sirna-Loaded PLGA-TPGS Nanoparticles in Vitro and in Vivo

Selective activity of various antiviral compounds against HHV-7 infection

Effect of Amino Acid Replacements, Additions and Deletions on the Antiviral Activity of A Peptide Derived from the Hiv-1 Gp41 Sequence

Antiviral potential of phenolic compounds against HSV-1: In-vitro study

Delineation of Interfaces on Human Alpha-Defensins Critical for Human Adenovirus and Human Papillomavirus Inhibition

Inactivation of cell-free HIV-1 by designing potent peptides based on mutations in the CD4 binding site

The GA-Hecate Peptide inhibits the ZIKV Replicative Cycle in Different Steps and can Inhibit the Flavivirus NS2B-NS3 Protease after Cell Infection

IN VITRO INfIBITION OF HHV-1 REPLICATION BY INOSINE PRANOBEX AND INTERFERON-α